News

The breakthrough designation for the drug is especially for HSCT-TMA patients with persistent TMA in spite of modification of immunosuppressive therapy. OMS721 is a human monoclonal antibody that

The first Phase 3 study will evaluate approximately 360 people with CF who have one copy of the F508del mutation and one minimal function mutation and is designed to support

Endo is paying approximately $190 million in total for Somerset Therapeutics and Wintac's business. Together, the acquisitions will secure for Endo's Par Sterile injectable business Somerset Therapeutics' commercial

The European Union patent and trademark office (EPO) has approved the EU patent application no. 08717866.1 (anti-androgen peptides and uses thereof in cancer therapy), which covered the firm’s

ADCT clinical development senior vice president and chief medical officer Dr Jay Feingold said: "We are very pleased with the efficacy and tolerability achieved with our lead hematological

Venrock led the Series B financing and was joined by five additional new investors: Andera (formerly Edmond de Rothschild), Cormorant Asset Management, HBM Healthcare Investments, Fresenius Medical Care

Risankizumab is a humanized monoclonal antibody, designed to selectively inhibit IL-23 by binding to its p19 subunit. IL-23 is an important cytokine involved in inflammatory processes, and is

The new indication is for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. It is also indicated to reduce

This randomised, open-label, multi-centre trial assessed the efficacy and safety of the combination of Imfinzi (durvalumab) plus tremelimumab, as well as Imfinzi and tremelimumab monotherapies, versus standard-of-care chemotherapy